Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual EGFR targeting with cetuximab + afatinib versus cetuximab in chemotherapy-refractory wtKRAS metastatic colorectal cancer
2012-000167-25Phase 2Completed
- Sponsor
- Unicancer
- Start
- Aug 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal cancer (CRC) comparing Cetuximab + afatinib with Cetuximab alone (2 arms). Primary endpoint: Non-progression rate at 6 months. Started Aug 2012; status: completed.
02
Drugs
cetuximabafatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2012-000167-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000167-25.